Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare ...

Pfizer shares were rising early Tuesday after the company reported fourth-quarter earnings and revenue that came in ahead of ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

A study done after the respiratory syncytial virus shots were approved suggests that people given GSK’s Arexvy and Pfizer’s Abrysvo may be at increased risk of Guillain-Barré syndrome for 42 ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

One Zelienople child survived a serious health scare after coming down with respiratory syncytial virus in late January. The ...

A virus rapidly spreading in China is also circulating in the United States, causing concern among health experts.

For most people RSV is like a cold, but for infants and older people it can lead to serious infections. Here's what to know.